Medicine and Dentistry
Chronic Kidney Disease
100%
Musculoskeletal Disease
95%
Disease Exacerbation
79%
Lupus Nephritis
47%
Sarcopenia
47%
Lupus Erythematosus
47%
Connective Tissue Disease
47%
Pulmonary Hypertension
47%
Peripheral Vasodilating Agent
47%
Disease Modifying Antirheumatic Drug
47%
Combination Therapy
47%
Systemic Lupus Erythematosus
47%
Disease Activity
47%
Biological Product
47%
Rheumatoid Arthritis
47%
Rheumatic Disease
47%
Trimethoprim/Sulfamethoxazole
47%
Adverse Drug Reaction
47%
Creatinine
35%
Monotherapy
27%
Glucocorticoid
23%
Drug Megadose
23%
Bone Mass
19%
Anti-dsDNA Antibodies
15%
Body Weight
14%
Vasodilator Agent
13%
Systolic Blood Pressure
13%
Prednisolone
12%
Disease Duration
11%
C Reactive Protein
10%
Clinical Disease Activity Index
10%
Tocilizumab
10%
Glomerular Filtration Rate
9%
Mental Capacity
9%
Lymphocyte
8%
Adult Onset Still Disease
8%
Spontaneous Remission
7%
Lung Artery Pressure
6%
Hemodynamic
6%
Echocardiography
6%
Disease Course
6%
SLEDAI
6%
Proteomics
5%
TNF Inhibitor
5%
Abatacept
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Musculoskeletal Disease
95%
Disease Exacerbation
79%
Disease Activity
58%
Remission
55%
Systemic Lupus Erythematosus
47%
Sarcopenia
47%
Combination Therapy
47%
Rheumatoid Arthritis
47%
Disease Modifying Antirheumatic Drug
47%
Peripheral Vasodilating Agent
47%
Connective Tissue Disease
47%
Pulmonary Hypertension
47%
Biological Product
47%
Lupus Erythematosus Nephritis
47%
Rheumatic Disease
47%
Cotrimoxazole
47%
Adverse Drug Reaction
47%
Monotherapy
27%
Glucocorticoid
23%
Vasodilator Agent
13%
Creatinine
13%
Prednisolone
12%
Tocilizumab
10%
C Reactive Protein
10%
Adult Onset Still Disease
8%
Disease Course
6%
Abatacept
5%
Tumor Necrosis Factor Inhibitor
5%
Inflammation
5%
Keyphrases
Chronic Kidney Disease
52%
Rheumatoid Arthritis
47%
Renal Flare
47%
Kidney Disease Progression
47%
SARS-CoV-2 mRNA Vaccination
47%
Rheumatic musculoskeletal Disease
47%
Biologic Disease-modifying Antirheumatic Drugs
47%
Trimethoprim-sulfamethoxazole (TMP-SMX)
47%
Risk Factors
47%
Rheumatic Diseases
47%
Adverse Drug Reaction
47%
Musculoskeletal Disorders
47%
Index Score
15%
Tocilizumab
15%
C-reactive Protein Level
15%
Clinical Activity Score
15%
Consecutive Patients
12%
Calgranulin B
11%
Lymphocyte Count
8%
Adult-onset Still's Disease
8%
Multivariable
8%
C-means
7%
Abatacept
7%
Tumour Necrosis Factor Inhibitor (TNFi)
7%
Decreased Risk
7%
Rheumatoid Arthritis Patients
7%
Inflammation
7%
Early Combination Therapy
7%
Estimated Glomerular Filtration Rate
7%
Residual Disease Activity
6%
Assay Validation
5%